Trial reportJournal of thrombosis and haemostasis : JTH2020
Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel.
Trial report in Journal of thrombosis and haemostasis : JTH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 60 citations in OpenAlex.
- Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel.Journal of thrombosis and haemostasis : JTH · 2020Trial
- The Dilution Paradox in Extracellular Vesicle Flow Cytometry.Journal of extracellular vesicles · 2026Article
- Review
- Resolving the dilution paradox to improve the interpretation of extracellular vesicle biomarker studies.Research and practice in thrombosis and haemostasis · 2026Article
- Translational Barriers and Optimization Strategies for Remote Ischemic Conditioning to Enhance Stroke Cerebroprotection.Biomolecules · 2026Review
- Endothelial Cell-Derived Extracellular Vesicles Allow to Differentiate Between Various Endotypes of INOCA: A Multicentre, Prospective, Cohort Study.Journal of cardiovascular translational research · 2025Article
- Roles and Therapeutic Targeting of Exosomes in Sepsis-Induced Cardiomyopathy.Journal of cellular and molecular medicine · 2025Review
- Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery.Current opinion in hematology · 2025Review
- Extracellular vesicles as standard-of-care therapy: will fast-tracking the regulatory processes help achieve the goal?Regenerative medicine · 2024Review
- Prospective Quantitative and Phenotypic Analysis of Platelet-Derived Extracellular Vesicles and Its Clinical Relevance in Ischemic Stroke Patients.International journal of molecular sciences · 2024Article
- Traceable characterization of hollow organosilica beads as potential reference materials for extracellular vesicle measurements with optical techniques.Discover nano · 2024Article
- Clinical applications and challenges in the field of extracellular vesicles.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- Cell Surface Platelet Tissue Factor Expression: Regulation by P2YArteriosclerosis, thrombosis, and vascular biology · 2023Article
- Preventing swarm detection in extracellular vesicle flow cytometry: a clinically applicable procedure.Research and practice in thrombosis and haemostasis · 2023Article
- Plasma concentration of TMAO is an independent predictor of adverse outcomes in patients after acute myocardial infarction.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2023Article
- Extracellular Vesicles in Coronary Artery Disease.Advances in experimental medicine and biology · 2023Review
- Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study.Cardiovascular diabetology · 2022Observational
- Removal of platelets from blood plasma to improve the quality of extracellular vesicle research.Journal of thrombosis and haemostasis : JTH · 2022Article
- Review
- Diagnostic Performance of Circulating miRNAs and Extracellular Vesicles in Acute Ischemic Stroke.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet P2Y12 antagonist ticagrelor reduces mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown. Because activated platelets, leukocytes, and endothelial cells release proinflammatory and prothrombotic extracellular vesicles (EVs), we hypothesized that the release of EVs is more efficiently inhibited by ticagrelor compared to clopidogrel.
objectivesWe compared EV concentrations and EV procoagulant activity in plasma of patients after AMI treated with ticagrelor or clopidogrel.
methodsAfter percutaneous coronary intervention, 60 patients with first AMI were randomized to ticagrelor or clopidogrel. Flow cytometry was used to determine concentrations of EVs from activated platelets (CD61
resultsConcentrations of platelet, fibrinogen
conclusionsTicagrelor attenuates the increase of EV concentrations in plasma after acute myocardial infarction compared to clopidogrel. The ongoing release of EVs despite antiplatelet therapy might explain recurrent thrombotic events after AMI and worse clinical outcomes on clopidogrel compared to ticagrelor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.